Objectives: The aim of this study was to evaluate outcomes of valve-in-valve transcatheter aortic valve implantation (VIV-TAVI) in patients with degenerated small bioprostheses.
. Before secondary intervention, 25 patients were found to be in the New York Heart Association (NYHA) functional class III (n = 16; 59.3%) or IV (n = 9; 33.3%).
| Preoperative evaluation
Before the procedure, transesophageal echocardiography and multislice computed tomography (CT) were performed routinely in all patients to evaluate the aortic root dimensions, locate the coronary ostia, and choose the most appropriate size of the transcatheter prosthesis. Anatomy of the femoral artery was also assessed. The CT data set was analyzed using the dedicated OsiriX imaging software (Pixmeo, Geneva, Switzerland). A single patient requiring an emergency procedure underwent VIV-TAVI without a preoperative CT scan. In this case the aortic annular dimensions were calculated by means of transesophageal echocardiography.
All cases were carefully analyzed by the heart team which consisted of cardiac surgeons, cardiologists, and anesthesiologists. The indication for the reintervention was SVD in all cases. All patients had a high degree of stenosis and over half had significant insufficiency. In one patient the primary defect was isolated regurgitation. The findings of the preoperative echocardiography are summarized in Table 2 .
| Procedure
The procedural access was transfemoral in all patients. Conscious sedation with local anesthesia was used in 26 patients. General anesthesia was necessary in two individuals due to either a critical preoperative state or procedure-related acute cardiac tamponade. All failed bioprostheses were routinely predilated ( Figure 2 
| Assessment of outcomes
Transthoracic echocardiography was performed routinely at discharge and then 3 months later. All patients completed the follow-up period that lasted a median of (min-max) 29 months (0-71). Leading regurgitation (%) 1 (6.7)
| Statistical analysis
Aortic prosthesis mean PG ± SD (mmHg) 50.4 ± 20.2
Aortic prosthesis peak PG ± SD (mmHg) 84.4 ± 28.3
LVIDd ± SD (cm) 4.9 ± 0.6 Statistical significance was assumed at P < 0.05. Statistical analysis was computed with SPSS STATISTICS 24 (IBM Corp., Armonk, NY). 
| Long-term follow-up
Four patients died during the follow-up period, two of them as a result of pneumonia (after 2.8 years and 3.2 years, respectively) and two due to unknown reasons (13 months and 3.3 years following procedure).
One-, two-, and three-year probability of survival was 88.9 ± 6.0%, 84.7 ± 7.1%, and 76.2 ± 10.3%, respectively ( Figure 5 ).
Valve Academic Research Consortium-2 (VARC-2) composite endpoints are summarized in Table 4 . 18 Although we did not use any form of coronary ostia protection during the procedure, no coronary obstruction was observed in our series regardless of the previously implanted bioprosthesis.
The percutaneous approach allows for the procedure to be performed under local anesthesia; however, it carries a potential risk of conversion to unplanned sternotomy and general anesthesia. 19 Fröhlich et al 20 in a meta-analysis described the conversion rate from local to general anesthesia being as high as 6.3% and showed that local anesthesia was associated with significantly shorter procedure time and in-hospital stay. Ehret et al 21 suggested that local anesthesia is associated with favorable effects such as a reduced need for inotropic support and packed red blood cells transfusions. Having gained enough experience in the field of TAVI, it was possible to reduce the rate of general anesthesia to below 8%.
We analyzed only patients after transfemoral access that is considered to be the access of choice for TAVI interventions in our institution. It features not only a low invasiveness but also a greater feasibility in most of the cases. 7 In our center, only one patient with a small degenerate bioprosthesis underwent a subclavian approach due advanced stage of peripheral artery disease and was excluded from this study.
We did not observe an increased incidence of complete AV block requiring permanent pacemaker implantation in comparison with the previous reports. Five of our patients already had a pacemaker implanted before the aortic valve reintervention. The relatively low rate of new peacemaker implantations may be associated with the protective role of the failed bioprosthesis frame. 22, 23 Scholtz et al 24 reported no association between degenerated bioprosthesis size and a new pacemaker implantation rate after VIV-TAVI.
| CONCLUSIONS
Transfemoral VIV-TAVI in patients with small degenerated bioprostheses appears to be a promising alternative to surgery. Although the rate of residual gradient is relatively high, late clinical improvement seems to justify VIV-TAVI in this group of patients.
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